Knowledge base
1,824 claims across 19 domains
Every claim is an atomic argument with evidence, traceable to a source. Browse by domain or search semantically.
All 1,824ai alignment 395health 320internet finance 306space development 227entertainment 169grand strategy 141collective intelligence 52mechanisms 34teleological economics 30living agents 30cultural dynamics 29critical systems 24energy 23teleohumanity 18living capital 10robotics 5manufacturing 5technology 3unknown 3
OBBBA puts over 300 rural hospitals at risk of closure or service reduction because rural hospitals serve 40-60 percent Medicaid/uninsured patients who have no commercial insurance alternatives nearby
The Sheps Center analysis identifies over 300 rural hospitals facing potential closure, conversion, or service reductions due to OBBBA Medicaid and DSH cuts. The mechanism is revenue concentration: rural hospitals derive 40-60 percent of revenue from Medicaid and DSH payments, compared to urban hosp
OBBBA produces anticipatory economic damage as states cut Medicaid reimbursement rates and providers implement workforce reductions before federal provisions take effect
Chartis documents that states are reducing Medicaid reimbursement rates immediately in 2026, before OBBBA's federal provisions fully phase in, because they are anticipating reduced federal funding and adjusting state budgets preemptively. Simultaneously, healthcare organizations are announcing workf
OBBBA Medicaid work requirements and concurrent ACA subsidy expiration create a compound coverage loss event of 15-17M Americans by 2030 — the largest single reversal of health coverage expansion since before the ACA
OBBBA creates two simultaneous coverage loss pathways that compound rather than add linearly. First pathway: Medicaid work requirements (effective December 30, 2026) project 4.9-10.1M coverage losses by 2028 (Urban Institute). Second pathway: ACA enhanced premium tax credits expired January 1, 2026,
GLP-1 telehealth prescribing scales without mandatory eating disorder screening because FDA regulates marketing claims but not prescribing criteria, leaving systematic risk assessment gaps
FDA issued 70+ warning letters to GLP-1 telehealth companies for misleading marketing claims (FDA-approval claims, manufacturing claims), but these enforcement actions target marketing, not prescribing practices. No mandatory protocol exists to screen for eating disorders prior to GLP-1 prescribing.
OBBBA Medicaid cuts create fiscal externalities that exceed their savings because projected 2029 state GDP losses ($154B) exceed federal savings ($131B) through the $1.75-1.82 Medicaid spending multiplier
The Commonwealth Fund/GWU analysis projects that OBBBA's $863B Medicaid cuts (FY 2025-2034) and $295B SNAP cuts will eliminate 1.2 million jobs and reduce state GDPs by $154 billion in 2029 alone. The critical finding is that state GDP losses ($154B) exceed federal savings ($131B) in that single yea
The ACA marketplace cannot absorb Medicaid disenrollment when enhanced subsidies expire simultaneously because premium doubling eliminates the coverage transition pathway for low-income populations
The KFF March 2026 poll found that 9% of people enrolled in ACA marketplace plans in 2025 are now uninsured following the January 1, 2026 expiration of enhanced subsidies. This is empirical evidence of coverage loss, not projection. The enhanced subsidies (introduced under American Rescue Plan Act 2
OBBBA's $50B Rural Health Fund cannot offset ongoing DSH revenue losses because it is a one-time fund with compressed access window (November 5, 2025 deadline) rather than a structural replacement for continuous DSH payment streams
OBBBA includes a $50B Rural Health Fund over 5 years, positioned as the offset for rural hospital cuts. However, the fund's structure creates a temporal and functional mismatch with the problem it purports to solve. The application deadline of November 5, 2025 means most fund access occurred BEFORE
Algorithmic telehealth assessments structurally cannot identify complex eating disorder presentations because atypical anorexia and non-purging bulimia require clinical specialist judgment that online questionnaires lack
DePaul Journal of Health Law and Innovation analysis (April 2026) argues that telehealth's algorithmic assessments cannot capture the psychological complexity needed to identify eating disorder risk. Specific diagnostic gap: atypical anorexia nervosa (presenting in larger body) or non-purging bulimi
FDA GLP-1 telehealth warning letters target a concentrated network where 30+ percent of warned firms affiliate with just four medical groups, making regulatory action on four organizations potentially market-transforming
STAT News investigation reveals that at least 30% of the 70+ telehealth firms receiving FDA warning letters maintain public affiliations with just 4 nationwide medical groups: Beluga Health, OpenLoop, MD Integrations, and Telegra. This is an interconnected network structure, not isolated bad actors.
Medicaid work requirements produce administrative waste at 2:1 ratio to healthcare delivery as Georgia Pathways spent $54.2M on administration versus $26.1M on care for ~100 beneficiaries
Georgia Pathways, the state's Medicaid work requirement program, spent $54.2 million on program administration while delivering only $26.1 million in actual healthcare services over 12 months. This 2:1 administrative-to-care cost ratio served approximately 100 people during the measurement period. T
OBBBA Medicaid work requirements eliminate expansion coverage universally with no state-level protection pathway
Urban Institute's state-level modeling projects that expansion enrollment will fall by 37-68% in low mitigation scenarios, 30-54% in medium mitigation, and 18-33% in high mitigation scenarios. Critically, every expansion state loses coverage—there is no 'absorption' state that successfully protects
OBBBA Medicaid work requirements will reduce coverage more through documentation-failure disenrollment than through actual non-compliance, because 19-37% of compliant workers cannot prove compliance administratively
OBBBA's Medicaid work requirements (80 hours/month work or community engagement for expansion adults 19-64) will cause coverage loss primarily through documentation failure, not actual ineligibility. Urban Institute projects 4.9M losses in high-mitigation scenarios (states with strong exemption infr
US health coverage entered a multi-year cascade erosion from three overlapping events removing 30M+ low-income Americans from public coverage with no absorption mechanism
The US health coverage system experienced three sequential coverage-loss events between 2023-2030 that compound rather than substitute: (1) Medicaid unwinding from COVID-era continuous enrollment removed 20M+ enrollees (enrollment fell from 93M in March 2023 to 75.3M by January 2026, a 20% decline);
Medicaid work requirements cause 7,000-9,000 excess deaths annually through administrative disenrollment not ineligibility
A peer-reviewed modeling study published in The Lancet Regional Health – Americas projects that OBBBA Medicaid work requirements will cause 7,049-9,252 excess deaths annually across three coverage loss scenarios (4.8M-10.1M losing coverage). The study extends a previously validated modeling framewor
State Medicaid exemption infrastructure capacity determines work requirement mortality with 90% versus 30% death aversion
The Lancet study models state-level variation in excess deaths and finds that administrative capacity to implement automatic exemptions is the primary determinant of mortality outcomes, not underlying population health or ineligibility rates.
Medicaid work requirements produce 19-37% compliant worker disenrollment through documentation infrastructure failure not actual non-compliance
RWJF modeling projects that 19-37% of people who lose Medicaid coverage under work requirements will be individuals who already meet the work requirement but cannot adequately document their compliance. The mechanism is structural: proving 80 hours/month of qualifying activity requires submitting do
Psilocybin facilitator training costs ($9,359 mean, 160+ hours) create economic filtering toward already-credentialed healthcare workers despite program equity intentions, with 79% reporting moderate-to-severe financial strain and 57% already holding healthcare licenses
Oregon's psilocybin facilitator training programs charge $4,500-$12,000 tuition (mean $9,359) for 120-200 hours of coursework plus 40-hour practicum, typically spanning 8 months. Despite 50% of programs offering scholarships for equity/inclusion, 79% of trainees reported the training costs created m
Conservative state psychedelic research authorization is enabled by veteran constituency that transcends partisan politics rather than general mental health advocacy
Texas represents the most conservative large state in the US, yet authorized $50M for Schedule I psychedelic drug research through SB 2308 in December 2025, with potential $50M federal ARPA-H match directed by Trump executive order in April 2026. The political enabling mechanism is veteran-specific:
Federal Medicaid work requirements project 4.9-10.1M coverage losses by 2028 representing the largest single structural setback to value-based care transition in a decade
RWJF projects 4.9-10.1 million people will lose Medicaid coverage specifically from work requirements by 2028, compared to CBO's 11.8M total OBBBA Medicaid impact by 2034. This means work requirements alone account for 40-85% of projected Medicaid losses, making them the dominant coverage loss mecha
Ibogaine demonstrates strongest single-session evidence for opioid use disorder among psychedelics but cardiac safety requirements delay FDA approval 4-5 years beyond psilocybin
The Texas IMPACT consortium ($50M state + $50M federal) represents the largest state-sponsored psychedelic research investment targeting opioid use disorder, the highest-mortality addiction crisis (79,384 overdose deaths in 2024). MAPS Phase 2 trials demonstrate 70-75% abstinence at 1 month, and ibo
Oregon's psilocybin access gap is a demand-side cost failure, not a supply-side capacity problem — facilitators have capacity for 60,000 clients/year but only 4,500/year are being served because session costs ($1,200-3,000) are uninsured and out-of-pocket
Oregon licensed approximately 500 psilocybin facilitators by Q1 2026, each with capacity to serve ~10 clients/month (mean intended monthly clients from survey). This creates theoretical capacity of 60,000 clients/year. However, Oregon's actual utilization in Q1 2025 was 1,509 clients in 4 months, pr
Medicaid work requirement implementation precedes federal exemption guidance, creating guaranteed wrongful termination gap for medically frail populations
Nebraska's May 1, 2026 work requirement implementation exposes a critical regulatory sequencing failure: the state is enforcing 80-hour monthly activity requirements before the federal government has defined 'medically frail' — the central exemption category. Exemptions include medical issues, pregn
US life expectancy recovery to all-time high in 2024 reflects acute mortality improvement that leaves structural metabolic threats intact
CDC NCHS reports US life expectancy reached an all-time high of 79.0 years in 2024, surpassing the pre-COVID 2019 level of 78.8 years. The primary driver was a 26.2% year-over-year decline in drug overdose deaths (from 31.3 to 23.1 per 100K), with synthetic opioid deaths falling 35.6%. This represen
MDMA-assisted therapy's FDA rejection reveals that clinical efficacy is necessary but insufficient for regulatory approval when functional unblinding invalidates self-reported outcomes in psychiatry trials
The FDA rejected Lykos Therapeutics' MDMA-assisted therapy for PTSD despite statistically significant Phase 3 efficacy (MAPP1 and MAPP2 trials showed CAPS-5 score reductions). The rejection centered on functional unblinding: MDMA's pronounced empathogenic and euphoric effects mean participants relia
IV magnesium protocol demonstrates ibogaine's cardiac risk is manageable in supervised clinical settings addressing the primary safety barrier to Phase 3 trials
Ibogaine is known to cause QT prolongation, a potentially fatal heart arrhythmia, with more than 30 deaths reported in the medical literature. This cardiac risk has been the primary barrier to clinical development in regulated settings. The Stanford protocol administered ibogaine with intravenous ma
Page 1 of 13